About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

PHA-739358 for the Treatment of Multiple Myeloma

NCT00872300·4 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Nerviano Medical Sciences

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

active multiple myeloma progressing after at least 2 prior lines of treatment
measurable disease
t(4;14) translocation
life expectancy of at least 3 months

You may not be if

uncontrolled hypertension
myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months.
pregnancy or breast feeding
active infections, including HIV

The record

StatusTerminated

PhasePhase 2

Taking part7

StartedOct 2008

UpdatedMay 28, 2014

Conditions

Multiple Myeloma

Where4

MAYO Clinic
Scottsdale, Arizona, United States
The Robert H Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
Hôpital Huriez, Centre Hospitalier Régional Universitaire de Lille
Lille, France

Clareo Health | PHA-739358 for the Treatment of Multiple Myeloma